JAK-STAT3 Pathway Activity Determination Using Gene Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack an accurate way to determine the activity level of the JAK-STAT3 cellular signaling pathway, which is crucial for identifying tumor behavior and selecting appropriate therapeutic treatments, as existing assays cannot assess the functional state of this pathway effectively.
Innovation Solution
A method and apparatus that calculate the activity level of the JAK-STAT3 cellular signaling pathway by measuring the expression levels of a unique set of target genes using a calibrated pathway model, allowing for the determination of the pathway's activity status and guiding therapeutic decisions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If existing assays are used to determine pathway activity, then the assessment process is simple, but the measurement precision is insufficient to accurately determine JAK-STAT3 pathway activity levels
Solution Approach 1:
The patent segments the JAK-STAT3 pathway assessment into multiple discrete gene expression measurements (STAT3, SOCS3, BCL3, BIRC5, CD274, FOS, HIF1A, HSP90AA1, HSP90AB1, MMP1, MYC) rather than using a single assay. Each gene's expression level is measured and weighted independently, then combined to provide a comprehensive pathway activity score, thereby improving measurement precision through multi-parameter analysis.
Solution Approach 2:
The patent transforms the assessment from qualitative existing assays to quantitative gene expression measurements with specific weightings. By assigning different weights to different genes based on their relevance to JAK-STAT3 pathway activity and using calibrated mathematical models, the system converts biological complexity into measurable parameters that can be accurately quantified and compared.
2Measurement precision
If a unique combination of target genes is measured, then the disease characterization accuracy is improved, but the quantity of substance (genes to be measured) increases
Solution Approach 1:
The patent extracts only the most relevant genes from the entire genome that are specifically associated with JAK-STAT3 pathway activity. By identifying and measuring only these 11 key target genes rather than performing whole-genome analysis, the system achieves high disease characterization accuracy while limiting the quantity of measurements to a manageable and clinically feasible set.
Solution Approach 2:
The patent applies different weights to different genes based on their local importance to pathway activity. Not all genes contribute equally to JAK-STAT3 signaling; some genes like STAT3 and SOCS3 are more directly involved and receive higher weights in the calculation algorithm, optimizing the information gained from each measurement while minimizing the total number of genes that must be assessed.
3Adaptability or versatility
If gene expression levels of multiple target genes are measured and processed, then the treatment personalization is improved, but the loss of time in processing and analyzing data increases
Solution Approach 1:
The patent performs preliminary actions by pre-calibrating the mathematical model with known pathway activity states and pre-determining the optimal weights for each gene. This calibration phase is completed beforehand, so that during clinical application, the system only needs to measure gene expression levels and apply the pre-established algorithm, significantly reducing the time required for data processing and enabling rapid treatment decisions.
Solution Approach 2:
The patent creates a computational model that copies and simulates the complex biological pathway interactions in silico. Rather than requiring complex wet-lab experiments to assess pathway activity, the system uses gene expression data to generate a virtual representation of pathway state through mathematical calculations, dramatically reducing processing time while maintaining accuracy.
Data Source
AI summary
A bioinformatics process which provides an improved means to detect a JAK-STAT3 cellular signaling pathway in a subject, such as a human, based on the expression levels of at least three unique target genes of the JAK-STAT3 cellular signaling pathway measured in a sample. The invention includes an apparatus comprising a digital processor configured to perform such a method, a non-transitory storage medium storing instructions that are executable by a digital processing device to perform such a method, and a computer program comprising program code means for causing a digital processing device to perform such a method. Kits are also provided for measuring expression levels of unique sets of JAK-STAT3 cellular signaling pathway target genes.